Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective

References

• Abboud, G., Kaplowitz, N. (2007). Drug-induced liver injury. Drug Saf 30:277–294.
   PubMed Web of Science ®Google Scholar
• Anders, M. W. (2005). Formation and toxicity of anesthetic degradation products. Annu Rev Pharmacol Toxicol 45:147–176.
   PubMed Web of Science ®Google Scholar
• Anders, M. W., Dekant, W. (1998). Glutathione-dependent bioactivation of haloalkenes. Annu Rev Pharmacol Toxicol 38:501–537.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. (2006). Press release. Available at: www.astrazeneca.com/media/latest-press-releases/2006. (Accessed February 7, 2009).
   Google Scholar
• Baer, B. R., Wienkers, L. C., Rock, D. A. (2007). Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954–964.
   PubMed Web of Science ®Google Scholar
• Baillie, T. A. (2008). Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Cehm Res Toxicol 21:129–137.
   PubMed Web of Science ®Google Scholar
• Baillie, T. A., Slatter, J. G. (1991). Glutathione—a vehicle for the transport of chemically reactive metabolites. Acc Chem Res 24:264–270.
   Web of Science ®Google Scholar
• Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., et al. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444–1454.
   PubMed Web of Science ®Google Scholar
• Baughman, T. M., Graham, R. A., Wells-Knecht, K., Silver, I. S., Tyler, L. O., Wells-Knecht, M., et al. (2005). Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos 33:733–738.
   PubMed Web of Science ®Google Scholar
• Bauman, J. N., Frederick, K. S., Sawant, A., Walsky, R. L., Cox, L. M., Obach, R. S., et al. (2008). Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab Dispos 36:1016–1029.
   PubMed Web of Science ®Google Scholar
• Beaune, P., Dansette, P. M., Mansuy, D., Kiffel, L., Finck, M., Amar, C., et al. (1987). Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A 84:551–555.
   PubMed Web of Science ®Google Scholar
• Benson, M. D., Aldo-Benson, M., Brandt, K. D. (1985). Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis. Semin Arthr Rheum 15:65–67.
   PubMed Web of Science ®Google Scholar
• Bhaskaran, K., Hamouda, O., Sannes, M., Boufassa, F., Johnson, A. M., Lambert, P. C., et al. (2008). Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300:51–59.
   PubMed Web of Science ®Google Scholar
• Blain, P. G., Battershill, J. M., Venitt, S., Copper, C. C., Fielder, R. J. (1998). Consideration of short-term carcinogenicity tests using transgenic mouse models. Mutat Res 403:259–263.
   PubMed Web of Science ®Google Scholar
• Boelisterli, U. A., Hsiao, C-J. J. (2008). The heterozygous Sod2+/- mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today 13:982–988.
   PubMed Web of Science ®Google Scholar
• Borzelleca, J. F. (2000). Paracelsus: herald of modern toxicology. Toxicol Sci 53:2–4.
   PubMed Web of Science ®Google Scholar
• Bourdi, M., Chen, W., Peter, R. M., Martin, J. L., Buters, J. T. M., Nelson, S. D., et al. (1996). Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 9:1159–1166.
   PubMed Web of Science ®Google Scholar
• Brinker, A. D., Wassel, R. T., Lyndly, J., Serrano, J., Avigan, M., Lee, W. M., et al. (2009). Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49:250–257.
   PubMed Web of Science ®Google Scholar
• Brune, K. (2007). Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin 23:2985–2995.
   PubMed Web of Science ®Google Scholar
• Caraco, Y., Blotnick, S., Muszkat, M. (2008). CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective, randomized, controlled study. Clin Pharmacol Ther 83:460–470.
   PubMed Web of Science ®Google Scholar
• Carlson, T. J., Fisher, M. B. (2008). Recent advances in high-throughput screening for ADME properties. Comb Chem High Throughput Screen 11:258–264.
   PubMed Web of Science ®Google Scholar
• Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., et al. (2008). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135:1924–1934.
   PubMed Web of Science ®Google Scholar
• Chen, C., Krausz, K. W., Shah, Y. M., Idle, J. R., Gonzalez, F. J. (2009). Serum metabolomics reveals irreversible inhibition of fatty acid β-oxidation through the suppression of PPARα activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol 22:699–707.
   PubMed Web of Science ®Google Scholar
• Chen, Q., Doss, G. A., Tung, E. C., Liu, W., Tang, Y. S., Braun, M. P., et al. (2006). Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos 34:145–151.
   PubMed Web of Science ®Google Scholar
• Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., et al. (2002). Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907–914.
   PubMed Web of Science ®Google Scholar
• Chen, W., Shockcor, J. P., Tonge, R., Hunter, A., Gartner, C., Nelson, S. D. (1999). Protein and nonprotein cysteinyl thiol modification by N-acetyl-p-benzoquinone imine via a novel ipso adduct. Biochemistry 38:8159–8166.
   PubMed Web of Science ®Google Scholar
• Clayton, T. A., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., et al. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073–1077.
   PubMed Web of Science ®Google Scholar
• Clercq, E. D. (2009). Anti-HIV drugs: 25 compounds approvde within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307–320.
   PubMed Web of Science ®Google Scholar
• Colacino, J. M. (1996). Mechanism for the anti-hepatitis B virus activity and mitochondrial toxicity if fialuridine (FIAU). Antiviral Res 29:125–139.
   PubMed Web of Science ®Google Scholar
• Cote, J-F., Kirzin, S., Kramar, A., Mosnier, J-F., Diebold, M-D., Soubeyran, I., et al. (2007). UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269–3275.
   PubMed Web of Science ®Google Scholar
• Cullen, J. M., Miller, R. T. (2006). The role of pathology in the identification of drug-induced hepatic toxicity. Exp Opin Drug Metab Toxicol 2:241–247.
   PubMed Web of Science ®Google Scholar
• Day, R. O., McLachlan, A. J., Graham, G. G., Williams, K. M. (1999). Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 36:191–210.
   PubMed Web of Science ®Google Scholar
• Day, S. H., Mao, A., White, R., Schulz-Utermoehl, T., Miller, R., Beconi, M. G. (2005). A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J Pharmacol Toxicol Meth 52:278–285.
   PubMedGoogle Scholar
• de Leon, J., Susce, M. T., Murray-Carmichael, E. (2006). The AmpliChip™ CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 10:135–151.
   PubMed Web of Science ®Google Scholar
• Debbage, P. (2009). Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15:153–172.
   PubMed Web of Science ®Google Scholar
• Degoul, F., Sutton, A., Mansouri, A., Cepanec, C., Degott, C., Fromenty, B., et al. (2001). Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcohol liver disease. Gastroenterology 120:1468–1474.
   PubMed Web of Science ®Google Scholar
• DeLeve, L. D., Kaplowitz, N. (1991). Glutathione metabolism and its role in hepatotoxicity. Pharm Ther 52:287–305.
   PubMed Web of Science ®Google Scholar
• DeSanty, K. P., Amabile, C. M. (2007). Antidepressant-induced liver injury. Ann Pharmacother 41:1201–1211.
   PubMed Web of Science ®Google Scholar
• Dieckhaus, C. M., Fernandez-Metzler, C. L., King, R., Krolikowski, P. H., Baillie, T. A. (2005). Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem Res Toxicol 18:630–638.
   PubMed Web of Science ®Google Scholar
• Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743.
   PubMed Web of Science ®Google Scholar
• Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., et al. (2008). In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103:335–345.
   PubMed Web of Science ®Google Scholar
• Eastin, W. C., Haseman, J. K., Mahler, J. F., Bucher, J. R. (1998). Testing compounds in genetically altered mice. Toxicol Pathol 26:461–473.
   PubMed Web of Science ®Google Scholar
• Erives, G. V., Lau, S. S., Monks, T. J. (2008). Accumulation of neurotoxic thioether metabolites of 3,4-(±)-methylenedioxymethamphetamine in rat brain. J Pharmacol Exp Ther 324:284–292.
   PubMed Web of Science ®Google Scholar
• Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., Baillie, T. A. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16.
   PubMed Web of Science ®Google Scholar
• Evista®. Prescribing information. (2008) Available at: www.evista.com. (Accessed January 10, 2009).
   Google Scholar
• Fernandes, N, Geller, S. A., Fong, T-L. (1998). Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 93:459–460.
   PubMed Web of Science ®Google Scholar
• Fernandes, N. F., Martin, R. R., Schenker, S. (2000). Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am J Gastroenterol 95:532–535.
   PubMed Web of Science ®Google Scholar
• FDA. (2009). Tables of valid genomic biomarkers in the context of approved drug labels. Available at: www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/default.htm. (Accessed January 17, 2009).
   Google Scholar
• Funk, C., Pantze, M., Jehle, L., Ponelle, C., Scheuermann, G., Lazendic, M., et al. (2001a). Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats: correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (BSEP) by troglitazone and troglitazone sulfate. Toxicology 167:83–98.
   PubMed Web of Science ®Google Scholar
• Funk, C., Ponelle, C., Scheuermann, G., Pantze, M. (2001b). Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (BSEP) in the rat. Mol Pharmacol 59:627–635.
   PubMed Web of Science ®Google Scholar
• Gan, J., Ruan, Q., He, B., Zhu, M., Shyu, W. C., Humphreys, W. G. (2009). In vitro screening of 50 highly prescribed drugs for thiol adduct formation—comparison of potential for drug-induced toxicity and extent of adduct formation. Chem Res Toxicol 22:690–698.
   PubMed Web of Science ®Google Scholar
• Ghanbari, F., Rowland-Yeo, K., Bloomer, J. C., Clarke, S. E., Lennard, M. S., Tucker, G. T., et al. (2006). A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro–in vivo extrapolation. Curr Drug Metab 7:315–334.
   PubMed Web of Science ®Google Scholar
• Glatt, H. (1997). Bioactivation of mutagens via sulfation. FASEB J 11:314–321.
   PubMed Web of Science ®Google Scholar
• Greaves, P., Williams, A., Eve, M. (2004). First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 3:226–236.
   PubMed Web of Science ®Google Scholar
• Greene, D. S., Barbhaiya, R. H. (1997). Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 33:260–275.
   PubMed Web of Science ®Google Scholar
• Guengerich, F. P., MacDonald, T. L. (1990). Mechanism of cytochrome P-450 catalysis. FASEB J 4:2453–2459.
   PubMed Web of Science ®Google Scholar
• Hagmann, W. K. (2008). The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Arch Pharm Chem Life Sci 341:405–411.
   PubMed Web of Science ®Google Scholar
• Hanna, P. E. (1996). Metabolic activation and detoxification of arylamines. Curr Med Chem 3:195–210.
   Web of Science ®Google Scholar
• Hargus, S. J., Martin, B. M., George, J. W., Pohl, L. R. (1995). Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug, diclofenac. Chem Res Toxicol 8:993–996.
   PubMed Web of Science ®Google Scholar
• He, K., Woolf, T. F., Hollenberg, P. F. (1999). Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 288:791–797.
   PubMed Web of Science ®Google Scholar
• Herceptin. Package insert. (2003) Available at: www.genentechaccesssolutions.com/herceptin/professional/forms/PI.jsp. (Accessed February 7, 2009).
   Google Scholar
• Hinson, J. A., Reid, A. B., McCullough S. S., James, L. P. (2004). Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev 36:805–822.
   PubMed Web of Science ®Google Scholar
• Hinz, B., Brune, K. (2008). Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci 29:391–397.
   PubMed Web of Science ®Google Scholar
• Honma, W., Shimada, M., Sasano, H., Ozawa, S., Miyata, M., Nagata, K., et al. (2002). Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944–949.
   PubMed Web of Science ®Google Scholar
• Huang, Y-S., Su, W-J., Huang, Y-H., Chen, C-Y., Chang, F-Y., Lin, H-C., et al. (2007). Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 47:128–134.
   PubMed Web of Science ®Google Scholar
• Ito, K., Ogihara, K., Kanamitsu, S-I., Itoh, T. (2003). Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945–954.
   PubMed Web of Science ®Google Scholar
• Iverson, S. L., Uetrecht, J. P. (2001). Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol 14:175–181.
   PubMed Web of Science ®Google Scholar
• Jaeschke, H. (2005). Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity. Exp Opin. Drug Metab Toxicol 1:389–397.
   PubMed Web of Science ®Google Scholar
• Jaeschke, H., Bajt M. L. (2006). Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 89:31–41.
   PubMed Web of Science ®Google Scholar
• Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., Lemasters, J. J. (2002). Mechanisms of hepatotoxicity. Toxicol Sci 65:166–176.
   PubMed Web of Science ®Google Scholar
• James, L. P., Capparelli, E. V., Simpson, P. M., Letzig, L., Roberts, D., Hinson, J. A., et al. (2008). Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther 84:684–690.
   PubMed Web of Science ®Google Scholar
• Jones, A. F., Vale, J. A. (1993). Paracetamol poisoning and the kidney. J Clin Pharm Ther 18:5–8.
   PubMed Web of Science ®Google Scholar
• Jones, D. C., Duvauchelle, C. D., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R. et, al. (2005). Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313:422–431.
   PubMed Web of Science ®Google Scholar
• Kaitin, K. I. (2008). Obstacles and opportunities in new drug development. Clin Pharmacol Ther 83:210–212.
   PubMed Web of Science ®Google Scholar
• Kalgutkar, A. S., Soglia, J. R. (2005). Minimizing the potential for metabolic activation in drug discovery. Exp Opin Drug Metab Toxicol 1:91–142.
   PubMedGoogle Scholar
• Kalgutkar, A. S., Vaz, A. D. N., Lame, M. E., Henne, K. R., Soglia, J., Zhao, S. X., et al. (2005). Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 33:243–253.
   PubMed Web of Science ®Google Scholar
• Kashimshetty, R., Desai, V. G., Kale, V. M., Lee, T., Moland, C. L., Branham, W. S., et al. (2009). Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicol Appl Pharmcol 238:150–159.
   PubMed Web of Science ®Google Scholar
• Kassahun, K., Hu, P., Grillo, M. P., Davis, M. R., Jin, L., Baillie, T. A. (1994). Metabolic activation of unsaturated derivatives of valproic acid: identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem Biol Interact 90:253–275.
   PubMed Web of Science ®Google Scholar
• Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., et al. (2001). Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo: evidence for novel bioactivation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62–70.
   PubMed Web of Science ®Google Scholar
• Kenne, K., Skanberg, I., Glinghammar, B., Berson, A., Pessayre, D., Flinois, J-P., et al. (2008). Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 22:730–746.
   PubMed Web of Science ®Google Scholar
• Ketterer, B., Mulder, G. (1990). Glutathione conjugation. In:Mulder, G. J. (Ed.), Conjugation reaction in drug metabolism (pp 307–364). New York: Taylor & Francis.
   Google Scholar
• Khan, K. K., He, Y. Q., Correia, M. A., Halpert, J. R. (2002). Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos 30:985–990.
   PubMed Web of Science ®Google Scholar
• Kleiner, D. E., Gaffey, M. J., Sallie, R., Tsokos, M., Nichols, L., McKenzie, R., et al. (1997). Histopathology changes associated with fialuridine hepatotoxicity. Mod Pathol 10:192–199.
   PubMed Web of Science ®Google Scholar
• Kumar, S., Kassahun, K., Tschirret-Guth, R. A., Mitra, K., Baillie, T. A. (2008). Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps, and future directions. Curr Opin Drug Discov Dev 11:43–52.
   PubMed Web of Science ®Google Scholar
• Kola, I. (2008). The state of innovation in drug development. Clin Pharmacol Ther 83:227–230.
   PubMed Web of Science ®Google Scholar
• Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 90:451–459.
   PubMed Web of Science ®Google Scholar
• Labbe, G., Pessayre, D., Fromenty, B. (2008). Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fund Clin Pharmacol 22:335–353.
   PubMed Web of Science ®Google Scholar
• Lewis, W., Griniuviene, B., Tankersley, K. O., levine, E. S., Montione, R., Engelman, L., et al. (1997). Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 76:77–87.
   PubMed Web of Science ®Google Scholar
• Li, C., Olurinde, M. O., Hodges, L. M., Grillo M. P., Benet, L. Z. (2003). Covalent binding of 2-phenylpropionyl-S-acyl-CoA thioester to tissue proteins in vitro. Drug Metab Dispos 31:727–730.
   PubMed Web of Science ®Google Scholar
• Lim, H. K., Chen, J., Cook, K., Sensenhauser, C., Silva, J., Evans, D. C. (2008). A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry. Rapid Commun Mass Spectrom 22:1295–1311.
   PubMed Web of Science ®Google Scholar
• Lin, J. H. (1999). Role of pharmacokinetics in the discovery and development of indinavir. Adv Drug Deliv Rev 39:33–49.
   PubMed Web of Science ®Google Scholar
• Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., et al. (2008). SLCO1B1 variants and statin-induced myopathy—a genomewide study. NEJM 359:789–799.
   PubMed Web of Science ®Google Scholar
• Liu, X., Chen, C., Smith, B. J. (2008). Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 325:349–356.
   PubMed Web of Science ®Google Scholar
• Liu, Z-X., Kaplowitz, N. (2006). Role of innate immunity in acetaminophen-induced hepatotoxicity. Exp Opin Drug Metab Toxicol 2:493–503.
   PubMed Web of Science ®Google Scholar
• Lucena, M. I., Carvajal, A., Andrade, R. J., Velasco, A. (2003). Antidepressant-induced hepatotoxicity. Exp Opin Drug Saf 2:249–262.
   PubMedGoogle Scholar
• Madan, A., Usuki, E., Burton, A., Ogilvie, B. W., Parkinson, A. (2002). In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In:Rodrigues, A. D. (Ed.), Drug-drug interactions (pp 217–294). New York: Marcel Dekker.
   Google Scholar
• Mallat, A., Zafrani, E. S., Metreau, J. M., Dhumeaux, D. (1997). Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Digest Dis Sci 42:1486–1488.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun, S., Salazar, D. E., Bramer, S. L. (2004). Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44:179–187.
   PubMed Web of Science ®Google Scholar
• Manyike, P. T., Kharasch, E. D., Kalhorn, T. F., Slattery, J. T. (2000). Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther 67:275–282.
   PubMed Web of Science ®Google Scholar
• Martin, J. L., Plevak, D. J., Flannery, K. D., Charlton, M., Poterucha, J. J., Humphreys, C. E., et al. (1995). Hepatotoxicity after desflurane anesthesia. Anesthesiology 83:1125–1129.
   PubMed Web of Science ®Google Scholar
• Masubuchi, Y. (2006). Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 21:347–356.
   PubMed Web of Science ®Google Scholar
• McKenzie, R., Fried M. W., Sallie, R., Conjeevaram, H., DiBisceglie, A. M., Park, Y., et al. (1995). Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. NEJM 333:1099–1105.
   PubMed Web of Science ®Google Scholar
• Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008b). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518.
   PubMed Web of Science ®Google Scholar
• Mitchell, M. D., Elrick, M. M., Walgren, J. L., Mueller, R. A., Morris, D. L., Thompson, D. C. (2008a). Peptide-based in vitro assay for the detection of reactive metabolites. Chem Res Toxicol 21:859–868.
   PubMed Web of Science ®Google Scholar
• Monks, T. J., Lau, S. S. (1994). Glutathione conjugation as a mechanism for the transport of reactive metabolites. Adv Pharmacol 27:183–210.
   PubMedGoogle Scholar
• Monks, T. J, Lau, S. S. (1998). The pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu Rev Pharmacol Toxicol 38:229–255.
   PubMed Web of Science ®Google Scholar
• Mortishire-Smith, R. J., Skiles, G. L., Lawrence, J. W., Spence, S., Nicholls, A. W., Johnson, B. A., et al. (2004). Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem Res Toxicol 17:165–173.
   PubMed Web of Science ®Google Scholar
• Muldrew, K. L., James, L. P., Coop, L., McCullough, S. S., Hendrickson, H. P., Hinson, J. A., et al. (2002). Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos 30:446–451.
   PubMed Web of Science ®Google Scholar
• Mullin, R. (2003). Drug development costs about $1.7 billion. Chem Eng News 81:8.
   Web of Science ®Google Scholar
• Myers, T. G., Dietz, E. C., Anderson, N. L, Khairallah, E. A., Cohen, S. D., Nelson, S. D. (1995). A comparative study of mouse liver protein arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3’-hydroxyacetanilide. Chem Res Toxicol 8:403–413.
   PubMed Web of Science ®Google Scholar
• Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., et al. (2009). A zone clarification system for risk assessment of idiosyncratic toxicity using daily dose and covalent binding. Drug Metab Dispos 37:1970–1977.
   PubMed Web of Science ®Google Scholar
• Neuberger, J. M. (1990). Halothane and hepatitis: incidence, predisposing factors, and exposure guidelines. Drug Saf 5:28–38.
   PubMed Web of Science ®Google Scholar
• Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., et al. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429–440.
   PubMedGoogle Scholar
• Njoku, D., Laster, M. J., Gong, D. H., Eger II, E. I., Reed, G. F., Martin, J. L. (1997). Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 84:173–178.
   PubMed Web of Science ®Google Scholar
• Obach, R. S., Kalgutkar, A. S., Soglia, J. R., Zhao, S. X. (2008). Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 21:1814–1822.
   PubMed Web of Science ®Google Scholar
• Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56–67.
   PubMed Web of Science ®Google Scholar
• Ong, M. M. K., Latchoumycandane, C., Boelsterli, U. A. (2006). Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 97:205–213.
   PubMed Web of Science ®Google Scholar
• Oritiz de Montellano, P. R. (1989). Cytochrome P450 catalysis: radical intemediates and dehydrogenation reactions. Trends Pharmacol Sci 10:354–359.
   PubMed Web of Science ®Google Scholar
• Overdevest, J. B., Theodorescu, D., Lee, J. K. (2009). Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem 55:684–697.
   PubMed Web of Science ®Google Scholar
• Palovaara, S., Kivisto, K. T., Tapanainen, P., Manninen, P., Neuvonen, P., Laine, K. (2000). Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1’-hydroxylation. Clin Pharmacol 50:333–337.
   Google Scholar
• Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., Niemi, M. (2006). SLCO1B1 plotmorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genom 16:873–879.
   PubMed Web of Science ®Google Scholar
• Pohl, L. R. (1990). Drug-induced allergic hepatitis. Semin Liver Dis 10:305–315.
   PubMed Web of Science ®Google Scholar
• Pohl, L. R., Branchflower, R. V. (1981). Covalent binding of electrofilic metabolites to macromolecules. Meth Enzymol 77:43–50.
   PubMedGoogle Scholar
• Polasek, T. M., Miners, J. O. (2006). Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Pharmacokint Dispos 62:203–208.
   Google Scholar
• Ponchaut, S., van Hoof, F., Veitch, K. (1992). In vitro effects of valproate and valproate metabolites on mitochondrial oxidations: relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 43:2435–2442.
   PubMed Web of Science ®Google Scholar
• Prakash, C., Sharma, R., Gleave, M., Nedderman, A. (2008). In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr Drug Metab 9:952–964.
   PubMed Web of Science ®Google Scholar
• Rashed, M. S., Myers, T. G., Nelson, S. D. (1990). Hepatic protein arylation, glutathione depletion, and metabolites profiles of acetaminophen and a non-hepatotoxic regioisomer, 3’-hydroxyacetanilide, in the mouse. Drug Metab Dispos 18:765–770.
   PubMed Web of Science ®Google Scholar
• Raskind, J. Y., El-Chaar, G. M. (2000). The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34:630–638.
   PubMed Web of Science ®Google Scholar
• Rieder, M. J. (2009). Immune mediation of hypersensitivity adverse drug reactions: implications for therapy. Exp Opin Drug Saf 8:331–343.
   PubMed Web of Science ®Google Scholar
• Rodrigues, A. D., Winchell, G. A., Dobrinska, M. R. (2001). Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol 41:368–373.
   PubMed Web of Science ®Google Scholar
• Roth, R. A., Luyendyk, J. P., Maddox, J. F., Ganey, P. E. (2003). Inflammation and drug idiosyncrasy—is there a connection? J Pharmacol Exp Ther 307:1–8.
   PubMed Web of Science ®Google Scholar
• Ruepp, S. U., Tonge, R. P., Shaw, J., Wallis, N., Pognan, F. (2002). Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 65:135–150.
   PubMed Web of Science ®Google Scholar
• Samuel, K., Yin, W., Stearns, R. A., Tang, Y. S., Chaudhary, A. G., Jewell, J. P., et al. (2003). Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J Mass Spectrom 38:211–221.
   PubMed Web of Science ®Google Scholar
• Sanderson, J. P., Naisbitt, D. J., Park, B. K. (2006). Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J 8:E55–E64.
   PubMed Web of Science ®Google Scholar
• Scatena, R., Bottoni, P., Botta, G., Martorana, G. E., Giardina, B. (2007). The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 293:C12–C21.
   PubMed Web of Science ®Google Scholar
• Shakeri-Nejad, K., Stahlmann, R. (2006). Drug interactions during therapy with three major groups of antimicrobial agents. Exp Opin Pharmacother 7:639–651.
   PubMed Web of Science ®Google Scholar
• Shenton, J. M., Popovic, M., Chen, J., Masson, M. J., Uetrecht, J. P. (2005). Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female brown Norway rat. Chem Res Toxicol 18:1799–1813.
   PubMed Web of Science ®Google Scholar
• Silva, M. F. B., Ijst, L., Allers, P., Jakobs, C., Duran, M., de Almeida, I. T., et al. (2004). Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria. Drug Metab Dispos 32:1304–1310.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science 235:177–182.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against Hers for metastatic breast cancer that overexpresses Hers. NEJM 344:783–792.
   PubMed Web of Science ®Google Scholar
• Slavin, D. E., Schlichting, C. L., Freston, J. W. (2005). Rating the severity of the medical consequences of drug-induced liver injury. Regul Toxicol Pharmacol 43:134–140.
   PubMed Web of Science ®Google Scholar
• Smith, M. T. (2003). Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 16:679–687.
   PubMed Web of Science ®Google Scholar
• Somchit, N., Wade, L. T., Ramsay, L., Goldin, R. D., Kenna, J. G., Caldwell, J. (1997). Hepatotoxicity and hepatic protein adduct formation in rats dosed i.p. with diclofenac. Hum Exp Toxicol 16:401.
   Google Scholar
• Spahn-Langguth, H., Benet L. Z. (1992). Acyl glucuronides revisited: is the glucuronidation process a toxification as well as detoxification mechanism? Drug Metab Rev 24:5–48.
   PubMed Web of Science ®Google Scholar
• Stern, S. T., Bruno, M. K., Hennig, G. E., Horton, R. A., Roberts, J. C., Cohen, S. D. (2005a). Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity in CD-1 mice: I. Enhancement of acetaminophen nephrotoxicity by acetaminophen-cysteine. Toxicol Appl Pharmacol 202:151–159.
   PubMed Web of Science ®Google Scholar
• Stern, S. T., Bruno, M. K., Horton, R. A., Hill, D. W., Roberts, J. C., Cohen, S. D. (2005b). Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity in CD-1 mice: II. Possible involvement of the γ-glutamyl cycle. Toxicol Appl Pharmacol 202:160–171.
   PubMed Web of Science ®Google Scholar
• Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M, et al. (2008). Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-aids infection. J Med Chem 51:5843–5855.
   PubMed Web of Science ®Google Scholar
• Sun, J., Schnackenberg, L. K., Holland, R. D., Schmitt, T. C., Cantor, G. H., Dragan, Y. P., et al. (2008). Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J Chromatogr B 871:328–340.
   PubMed Web of Science ®Google Scholar
• Takakusa, H., Masumoto, H., Yukinaga, H., Makino, C., Nakayama, S., Okazaki, O., et al. (2008). Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos 36:1770–1779.
   PubMed Web of Science ®Google Scholar
• Tang, W. (2003). The metabolism of diclofenac—enzymology and toxicology perspectives. Curr Drug Metab 4:319–329.
   PubMed Web of Science ®Google Scholar
• Tang, W. (2007). Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Exp Opin Drug Metab Toxicol 3:407–420.
   PubMed Web of Science ®Google Scholar
• Tang, W., Abbott, F. S. (1996). Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation: LC/MS/MS characterization of the GSH-glucuronide di-conjugates. Chem Res Toxicol 9:517–526.
   PubMed Web of Science ®Google Scholar
• Tang, W., Borel, A. G., Abbott, F. S. (1996). Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione S-transferases. Drug Metab Dispos 24:436–446.
   PubMed Web of Science ®Google Scholar
• Tang, W., Lu, A. Y. H. (2009). Drug metabolism and pharmacokinetics in support of drug design. Curr Pharm Des 15:2170–2183.
   PubMed Web of Science ®Google Scholar
• Tang, W., Stearns, R. A., Wang, R. W., Miller, R. R., Chen, Q., Ngui, J., et al. (2008). Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists. Xenobiotica 38:1437–1457.
   PubMed Web of Science ®Google Scholar
• Tennant, B. C., Baldwin, B. H., Graham, L. A., Ascenzi, M. A., Hornbuckle, W. E., Rowland, P. H., et al. (1998). Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179–191.
   PubMed Web of Science ®Google Scholar
• Tirmenstein, M. A., Nelson, S. D. (1989). Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3’-hydroxyacetanilide, in mouse liver. J Biol Chem 264:9814–9819.
   PubMed Web of Science ®Google Scholar
• Tong, V., Teng, X. W., Chang, T. K. H., Abbott, F. S. (2005). Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 86:436–443.
   PubMed Web of Science ®Google Scholar
• Townsend, D. M., Hanigan, M. H. (2002). Inhibition of γ-glutamyl transpeptidase or cysteine S-conjugate β-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300:142–148.
   PubMed Web of Science ®Google Scholar
• Townsend, D. M., Tew, K. D., He, L., King, J. B., Hanigan, M. H. (2009). Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomed Pharmacother 63:79–85.
   PubMed Web of Science ®Google Scholar
• Uetrecht, J. (1999). New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol 12:387–395.
   PubMed Web of Science ®Google Scholar
• Uetrecht, J. (2006). Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab Rev 38:745–753.
   PubMed Web of Science ®Google Scholar
• Uetrecht, J. (2009). Immune-mediated adverse drug reactions. Chem Res Toxicol 22:24–34.
   PubMed Web of Science ®Google Scholar
• Umrethia, M., Ghosh, P., Majithya, R., Murthy, R. (2007). 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity. Cancer Invest 25:117–123.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan, K., Obach, R. S. (2007). Drug-drug interaction via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8:449–462.
   PubMed Web of Science ®Google Scholar
• Waley, S. G. (1985). Kinetics of suicide substrates: practical procedures for determining parameters. Biochem J 227:843–849.
   PubMed Web of Science ®Google Scholar
• Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., et al. (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106:4402–4407.
   PubMed Web of Science ®Google Scholar
• Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Maurel, P., Guzelian, P. S. (1986). Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J Biol Chem 261:6264–6271.
   PubMed Web of Science ®Google Scholar
• Westphal, J. F. (2000). Macrolide-induced clinically relevant drug interactions with cytochrome P450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin. Br J Clin Pharmacol 50:285–295.
   PubMed Web of Science ®Google Scholar
• Wen, B., Ma, L., Rodrigues, D., Zhu, M. (2008a). Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos 36:841–850.
   PubMed Web of Science ®Google Scholar
• Wen, B., Ma, L., S. D. Nelson, S.D., Zhu, M. (2008b). High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry. Anal Chem 80:1788–1799.
   PubMed Web of Science ®Google Scholar
• Williams, D. P. (2006). Toxicophores: investigations in drug safety. Toxicology 226:1–11.
   PubMed Web of Science ®Google Scholar
• Yamamoto, Y., Nakajima, M., Yamazaki, H., Yokoi, T. (2001). Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci 70:471–482.
   PubMed Web of Science ®Google Scholar
• Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., et al. (1999). Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260–1266.
   PubMed Web of Science ®Google Scholar
• Yuan, L., Kaplowitz, N. (2009). Glutathione in liver disease and hepatotoxicity. Mol Asp Med 30:29–41.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Chen, Q., Li, Y., Doss, G. A., Dean, B. J., Ngui, J. S., et al. (2005). In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinine-type metabolites. Chem Res Toxicol 18:675–685.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Gan, J. (2007). Protocols for assessment of in vitro and in vivo bioactivation potential of drug candidates. In:Zhang, D., Zhu, M., Humphreys, W. G. (Eds.), Drug metabolism in drug design and development: basic concepts and practice (pp 447–476). Hoboken, New Jersey, USA: John Wiley & Sons.
   Google Scholar
• Zhang, Z., Zhu, M., Tang, W. (2009). Metabolite identification and profiling in drug design: current practice and future directions. Curr Pharm Des 15:2220–2235.
   PubMed Web of Science ®Google Scholar
• Zuckermann, J. M. (2004). Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin N Am 18:621–649.
   PubMed Web of Science ®Google Scholar